File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Recent advances in the treatment of lymphomas
Title | Recent advances in the treatment of lymphomas |
---|---|
Authors | |
Keywords | Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Lymphoma, Extranodal Nk-T-Cell Lymphoma, Follicular Prednisone Vincristine |
Issue Date | 2010 |
Publisher | Scientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/ |
Citation | Journal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 22-24 How to Cite? |
Abstract | Malignant lymphoma is a common neoplasm and some are potentially curable if appropriate therapy is given. The use of the monoclonal anti-CD20 antibody rituximab in the management of follicular lymphoma has improved the outcome of patients. Rituximab and chemotherapy combination is now standard in the initial treatment of advanced-stage follicular lymphoma. Furthermore, rituximab maintenance therapy has also been shown to prolong progression-free survival in first clinical remission as well as in relapse following salvage therapy. In addition to rituximab, the use of purine analogue fludarabine in follicular lymphoma has also been shown to enhance the response rate. On the other hand, chemotherapy designed for the treatment of B-cell lymphoma is generally ineffective for NK/T-cell lymphoma, a highly malignant lymphoma that is prevalent in Asian countries. Recently, preliminary results from international study and our local centre have shown that the SMILE regimen (comprising dexamethasone, methotrexate, ifosphamide, L-asparaginase and etoposide) is very effective and would potentially improve the survival of patients with NK/T-cell lymphoma. © 2010 Hong Kong College of Radiologists. |
Persistent Identifier | http://hdl.handle.net/10722/163363 |
ISSN | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, E | en_US |
dc.contributor.author | Kwong, YL | en_US |
dc.date.accessioned | 2012-09-05T05:30:34Z | - |
dc.date.available | 2012-09-05T05:30:34Z | - |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Journal Of The Hong Kong College Of Radiologists, 2010, v. 13 n. 3 SUPPL., p. 22-24 | en_US |
dc.identifier.issn | 1029-5097 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163363 | - |
dc.description.abstract | Malignant lymphoma is a common neoplasm and some are potentially curable if appropriate therapy is given. The use of the monoclonal anti-CD20 antibody rituximab in the management of follicular lymphoma has improved the outcome of patients. Rituximab and chemotherapy combination is now standard in the initial treatment of advanced-stage follicular lymphoma. Furthermore, rituximab maintenance therapy has also been shown to prolong progression-free survival in first clinical remission as well as in relapse following salvage therapy. In addition to rituximab, the use of purine analogue fludarabine in follicular lymphoma has also been shown to enhance the response rate. On the other hand, chemotherapy designed for the treatment of B-cell lymphoma is generally ineffective for NK/T-cell lymphoma, a highly malignant lymphoma that is prevalent in Asian countries. Recently, preliminary results from international study and our local centre have shown that the SMILE regimen (comprising dexamethasone, methotrexate, ifosphamide, L-asparaginase and etoposide) is very effective and would potentially improve the survival of patients with NK/T-cell lymphoma. © 2010 Hong Kong College of Radiologists. | en_US |
dc.language | eng | en_US |
dc.publisher | Scientific Communications International Ltd. The Journal's web site is located at http://www.hkcr.org/ | en_US |
dc.relation.ispartof | Journal of the Hong Kong College of Radiologists | en_US |
dc.subject | Antibodies, Monoclonal | en_US |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en_US |
dc.subject | Lymphoma, Extranodal Nk-T-Cell | en_US |
dc.subject | Lymphoma, Follicular | en_US |
dc.subject | Prednisone | en_US |
dc.subject | Vincristine | en_US |
dc.title | Recent advances in the treatment of lymphomas | en_US |
dc.type | Article | en_US |
dc.identifier.email | Tse, E:ewctse@hku.hk | en_US |
dc.identifier.email | Kwong, YL:ylkwong@hku.hk | en_US |
dc.identifier.authority | Tse, E=rp00471 | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.scopus | eid_2-s2.0-79952066483 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-79952066483&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 13 | en_US |
dc.identifier.issue | 3 SUPPL. | en_US |
dc.identifier.spage | 22 | en_US |
dc.identifier.epage | 24 | en_US |
dc.publisher.place | Hong Kong | en_US |
dc.identifier.scopusauthorid | Tse, E=7005019454 | en_US |
dc.identifier.scopusauthorid | Kwong, YL=7102818954 | en_US |
dc.identifier.issnl | 1029-5097 | - |